インシデント高血圧の予測のためのプロテオミックリスクスコア
Minkwan Kim1, Hamed Tavolinejad2,3, Mateo Bustamante2,3
1Division of Cardiology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Republic of Korea (M.K.).
Hypertension (Dallas, Tex. : 1979)
|February 20, 2026
まとめ
新しいプロテオミックリスクスコア (ProtRS) は,従来のリスク要因と遺伝データを上回り,インシデント高血圧の予測を大幅に改善します. このプロテオミックアプローチは,高血圧リスクの階層化を強化し,疾患メカニズムへの洞察を提供します.
科学分野:
- 心血管疾患に関する研究
- プロテオミクスとバイオマーカーの発見
- 精密医療とは
背景:
- プロテオミクシグネチャーは,心臓代謝疾患の予測において有望であることが示されています.
- インシデント高血圧の正確な予測は,標的型予防戦略にとって極めて重要です.
研究 の 目的:
- プロテオミックリスクスコア (ProtRS) がインシデント高血圧の予測を向上させるかどうかを評価する.
- 既知の人口統計的,臨床的,遺伝的リスク要因を超えて,ProtRSの付加価値を評価する.
主な方法:
- ProtRSは,UK Biobank Proteomicsコホート (n=25,158) で罰せられたコックス回帰を使用して開発されました.
- ProtRSは,独立した英国バイオバンクテストセット (n=10,781) とAsklepios研究 (n=793) で検証されました.
- モデルのパフォーマンスは,コバリアートとポリジェニックリスクスコア (PRS) の調整を含む,ProtRSとそれ以外のリスク予測を比較することによって評価されました.
主要な成果:
- UK Biobankでは,より高いProtRSがインシデント高血圧と強く関連していた (HR, 1.68).
- ProtRSを追加することで,モデルフィット,差別 (C指数は0.745から0.765に増加) および再分類 (NRI,19%) が著しく改善されました.
- Asklepiosでの外部検証は,高血圧リスク (HR, 1.32) とProtRS関連性を確認し,モデル差別を改善しました.
結論:
- プロテオミックリスクスコア (ProtRS) は,現在の人口統計,臨床,遺伝情報を超えて,インシデント高血圧の予測を大幅に改善します.
- プロテオミックデータは,個別化された高血圧リスクの階層化のための貴重なツールを提供します.
- 経路分析は,中性粒子の脱粒化とPI3Kシグナル伝達を含む高血圧の発達に関する生物学的な洞察を示唆しています.
関連する概念動画
Hypertension II: Pathophysiology
1.1K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.1K
Genome-wide Association Studies-GWAS
15.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.8K
Hypertension III: Clinical Manifestations and Diagnostic Studies
640
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
640
Hypertension I: Introduction
1.0K
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
1.0K
Hypertension and Regulation of Blood Pressure
4.5K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.5K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
625
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
625

